Survodutide (development code BI 456906) is one of the more interesting molecules in the incretin pipeline because of what its second receptor does. Where semaglutide acts on the GLP-1 pathway alone, survodutide is a dual agonist of the GLP-1 receptor and the glucagon receptor. It is being developed jointly by Boehringer Ingelheim and Zealand Pharma, and it remains investigational — not yet approved for any use, anywhere, though as of mid-2026 it has moved from Phase 2 to positive, published Phase 3 results. Here is a straight read of the trial record, Phase 2 and Phase 3 both, and what it establishes so far.
What it is, and why the glucagon arm matters
Survodutide is a once-weekly subcutaneous peptide. The GLP-1 component does the familiar work: suppressing appetite and improving glycemic control. The distinctive piece is glucagon-receptor agonism. Glucagon, at these signaling levels, is thought to raise energy expenditure and promote mobilization of fat from the liver — so the design intent is to combine reduced calorie intake (GLP-1) with increased calorie burn and direct hepatic fat handling (glucagon). That mechanistic logic is also why survodutide has been tested not just for weight but specifically for liver disease.
It helps to place survodutide on the map of multi-receptor agonists. Tirzepatide pairs GLP-1 with GIP rather than glucagon (covered in our tirzepatide versus semaglutide comparison), while retatrutide goes further still, hitting GIP, GLP-1 and glucagon all at once — see our retatrutide Phase 2 evidence. Survodutide sits between them: two receptors, one of which is glucagon.
The Phase 2 obesity trial
In a 46-week, randomized, double-blind, placebo-controlled, dose-finding Phase 2 trial across 43 centers, 387 adults with obesity (BMI ≥27, without diabetes) were assigned to survodutide at 0.6, 2.4, 3.6 or 4.8 mg or placebo, once weekly.[1] At week 46, mean body-weight change was dose-dependent: about −14.9% at the top 4.8 mg dose, versus about −2.8% with placebo (with intermediate doses landing near −12.5% and −13.2%).[1]
Those magnitudes are broadly in the same territory as GLP-1 monotherapy and dual GIP/GLP-1 therapy, though cross-trial comparison is only suggestive. As with every incretin agent, the weight benefit comes partly from reduced lean mass as well as fat — a caveat we cover in GLP-1 and lean-mass loss. The obesity trial was not powered to settle that or long-term outcomes; it was a dose-finding study.
The Phase 2 MASH / liver trial
The liver trial is where survodutide's glucagon arm was most directly tested. In a 48-week Phase 2 trial, 293 adults with biopsy-confirmed metabolic dysfunction-associated steatohepatitis (MASH) and fibrosis stage F1–F3 were randomized to survodutide 2.4, 4.8 or 6.0 mg or placebo.[2]The primary endpoint — histologic improvement in MASH with no worsening of fibrosis — was met by 47%, 62% and 43% of participants across the three doses, versus 14% on placebo.[2]
Secondary readouts pointed the same direction: a decrease in liver fat content of at least 30% occurred in 63%, 67% and 57% of survodutide participants versus 14% on placebo, and improvement in fibrosis by at least one stage occurred in 34%, 36% and 34% versus 22% on placebo.[2] The authors concluded survodutide was superior to placebo for MASH improvement without worsening fibrosis, and that the result warranted Phase 3 investigation.[2]
Update: Phase 3 confirms the Phase 2 signal
By mid-2026 the dose-finding Phase 2 data above had been followed by two published Phase 3 trials. SYNCHRONIZE-1 randomized 725 adults with obesity or overweight (without type 2 diabetes) to weekly survodutide 3.6 or 6.0 mg or placebo for 76 weeks, and reported mean weight loss of about −16.6% versus −3.2% on placebo — a statistically significant result consistent with, and slightly larger than, the earlier Phase 2 obesity signal.[4] On the liver side, SYNCHRONIZE-MASLD randomized 216 adults with obesity and metabolic dysfunction-associated steatotic liver disease to survodutide or placebo for 48 weeks and found 84.2% of treated participants achieved at least a 30% reduction in MRI-measured liver fat, with 61.0% normalizing liver fat entirely, alongside weight loss.[5] Both trials were presented at the American Diabetes Association’s 2026 Scientific Sessions and published in the New England Journal of Medicine and Nature Medicine, respectively — real, peer-reviewed confirmation that the Phase 2 signal held up in larger, longer, better-controlled trials.
The honest caveats
Two things deserve emphasis. First, tolerability: gastrointestinal side effects were common and dose-related. In the Phase 2 MASH trial, nausea (66% vs 23%), diarrhea (49% vs 23%) and vomiting (41% vs 4%) were all more frequent with survodutide than placebo, and serious adverse events occurred in 8% versus 7%.[2] The obesity trials reported the same GI-dominant pattern at both the Phase 2[1] and Phase 3[4] stage. Second, and still important: as of mid-2026 survodutide is not yet an approved medicine anywhere. Positive Phase 3 results are the step before a regulatory filing and review, not the same thing as approval — that process, and its timeline, was not yet complete as this page was last checked.
The honest bottom line
Survodutide is a genuinely dual-mechanism drug whose glucagon arm shows up in two ways: competitive weight loss and, more distinctively, strong liver-fat and MASH results — and by mid-2026 both effects had been confirmed in published Phase 3 trials, not just Phase 2. That combination is what makes it worth watching alongside other next-generation candidates such as oral orforglipron. But the honest label is still “strong Phase 3 data, not yet approved” — the regulatory review and the long-term, real-world safety picture are exactly what happens next. For now, that is the correct and limited claim.